Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 9/20 | 0.47 |
| ▸ | GSK3B | P49841 | 7/20 | 0.47 |
| ▸ | CDK1 | P06493 | 9/20 | 0.46 |
| ▸ | MERTK | Q12866 | 3/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 7/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 7/20 | 0.43 |
| ▸ | CDK9 | P50750 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL342481 | 1.00 | CDK2 (0.47) | CDK2GSK3BCDK1MERTKCHEK1 | |
| SCHEMBL343382 | 0.90 | MERTK (0.57) | CDK2GSK3BCDK1MERTKSYK | |
| SCHEMBL31299866 | 0.90 | MERTK (0.57) | CDK2GSK3BCDK1MERTKSYK | |
| SCHEMBL343383 | 0.90 | MERTK (0.57) | CDK2GSK3BCDK1MERTKSYK | |
| Hydrochloric Acid SCHEMBL31299841 | 0.89 | MERTK (0.56) | CDK2GSK3BCDK1MERTKSYK | |
| SCHEMBL341734 | 0.85 | STK3 (0.47) | CDK1MERTKSYKAURKACCNB1 | |
| SCHEMBL341735 | 0.85 | STK3 (0.47) | CDK1MERTKSYKAURKACCNB1 | |
| SCHEMBL343518 | 0.84 | MERTK (0.43) | CDK2CDK1MERTKSYKAURKA | |
| SCHEMBL343517 | 0.84 | MERTK (0.43) | CDK2CDK1MERTKSYKAURKA | |
| SCHEMBL343683 | 0.83 | MERTK (0.51) | MERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637529-B2 | Pyrazolo[3,4-d]pyrimidine compounds | AbbYie Inc. (US) | 2014-01-28 | — | — | US | claimed |
| US-20120015963-A1 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-01-19 | — | — | US | claimed |
| US-8637529-B2 | Pyrazolo[3,4-d]pyrimidine compounds | AbbYie Inc. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20120015963-A1 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015963-A1 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS | CHUK, MAP2K2, CDK3 | CDK2 6/4885GSK3B 573/4885CDK1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.